Q2 2014

Filed Feb 5, 2014 · 10-Q · 36 days after period end · 0001104659-14-006638

Q2 2014 · 10-Q

Revenue—

Net Income

-$168.16K

no prior Q2 2013 on file

EPS Diluted

-$0.02

no prior Q2 2013 on file

Operating Income-$163,275—

Operating Cash Flowderived-$222,729—

Same quarter

no prior Q2 2013 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ended Dec 31, 2013 · filed Feb 5, 2014 · 36 d after period end

Hepion Pharmaceuticals, Inc. · CIK 1583771 · Engraved from SEC EDGAR